Premium
Clinical efficacy and safety of a water‐soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas
Author(s) -
Rivera P.,
ÅkerlundDenneberg N.,
Bergvall K.,
Kessler M.,
Rowe A.,
Willmann M.,
Persson G.,
Kastengren Fröberg G.,
Westberg S.,
Euler H.
Publication year - 2013
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/j.1748-5827.2012.01304.x
Subject(s) - medicine , neutropenia , adverse effect , leukopenia , subclinical infection , clinical significance , paclitaxel , gastroenterology , surgery , chemotherapy
Objective To determine the clinical efficacy and safety of a cremophor‐free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours.Methods Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m 2 intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression‐free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events.Results Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression.Clinical Significance Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.